Atossa Therapeutics reports a wider Q1 GAAP loss as operating expenses rise to $9.9 million from $7.4 million a year earlier.
Atossa Therapeutics reported a first-quarter GAAP loss of $1.11 per share, reflecting increased financial pressure. The company’s net loss widened as operating expenses climbed to $9.9 million for the period ended March 31, 2026.
Operating expenses rose by $2.5 million compared to the same period in 2025, when expenses totaled $7.4 million. The increase was driven by higher research and development costs, as well as expanded operational activities.
No immediate market reaction was disclosed in the release.